Abstract
Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 378-386 |
| Number of pages | 9 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 82 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2012 |
Fingerprint
Keywords
- Cutaneous adverse events
- Guidelines
- Hand-foot skin reaction
- Prevention
- Sorafenib
- Targeted therapy
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
Cite this
Early detection, prevention and management of cutaneous adverse events due to sorafenib : Recommendations from the Sorafenib Working Group. / Bracarda, Sergio; Ruggeri, Enzo Maria; Monti, Marcello; Merlano, Marco; D'Angelo, Alessandro; Ferraù, Francesco; Cortesi, Enrico; Santoro, Armando.
In: Critical Reviews in Oncology/Hematology, Vol. 82, No. 3, 06.2012, p. 378-386.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early detection, prevention and management of cutaneous adverse events due to sorafenib
T2 - Recommendations from the Sorafenib Working Group
AU - Bracarda, Sergio
AU - Ruggeri, Enzo Maria
AU - Monti, Marcello
AU - Merlano, Marco
AU - D'Angelo, Alessandro
AU - Ferraù, Francesco
AU - Cortesi, Enrico
AU - Santoro, Armando
PY - 2012/6
Y1 - 2012/6
N2 - Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.
AB - Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.
KW - Cutaneous adverse events
KW - Guidelines
KW - Hand-foot skin reaction
KW - Prevention
KW - Sorafenib
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84861191918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861191918&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2011.08.005
DO - 10.1016/j.critrevonc.2011.08.005
M3 - Article
VL - 82
SP - 378
EP - 386
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 3
ER -